Will a new recipe for a myeloma drug pass the test?
NCT ID NCT06425991
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two versions of the drug teclistamab—one made with the current process and one with a new process—in 108 people with multiple myeloma that has come back or not responded to treatment. The main goal is to see if the body absorbs and handles both versions the same way. Participants receive the drug as a shot under the skin, and researchers will also monitor immune responses and tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Teclistamab (a drug given as a shot under the skin)
What this could lead to
If successful, this study could confirm that the new manufacturing process produces teclistamab that works just as well, ensuring a stable supply for patients.
What could go wrong
This is an early-phase study focused on drug levels in the body, not on proving the drug works better. It is small and may not show meaningful differences in how patients feel or their outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Papa Giovanni XXIII Bergamo
Bergamo, 24127, Italy
-
Asan Medical Center
Seoul, 05505, South Korea
-
Augusta University- Georgia Cancer Center
Augusta, Georgia, 30912, United States
-
Azienda Ospedaliera Spedali Civili di Brescia
Brescia, 25123, Italy
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
Baylor University Medical Center
Dallas, Texas, 75246, United States
-
Box Hill Hospital
Box Hill, 3128, Australia
-
CHRU de Lille Hopital Claude Huriez
Lille, 59037, France
-
CHU Nantes
Nantes, 44093, France
-
CHU de Bordeaux - Hospital Haut-Leveque
Pessac, 33604, France
-
Carmel Medical Center
Haifa, 3436212, Israel
-
Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli
Lublin, 20 090, Poland
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Cleveland Clinic Florida
Weston, Florida, 33331, United States
-
Clinica Univ. de Navarra
Pamplona, 31008, Spain
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
Derriford Hospital
Plymouth, PL6 8DH, United Kingdom
-
Dolnoslaskie Centrum Onkologii
Wroclaw, 53-439, Poland
-
Epworth Healthcare
Richmond, 3121, Australia
-
Flinders Medical Centre
Bedford Park, 5042, Australia
-
Hadassah University Hospita Ein Kerem
Jerusalem, 9112001, Israel
-
Hammersmith Hospital
London, W12 0HS, United Kingdom
-
Hosp Clinic de Barcelona
Barcelona, 08036, Spain
-
Hosp Clinico Univ de Salamanca
Salamanca, 37007, Spain
-
Hosp. Quiron Madrid Pozuelo
Pozuelo de Alarcón, 28223, Spain
-
Hosp. Univ. 12 de Octubre
Madrid, 28041, Spain
-
Hosp. Univ. Marques de Valdecilla
Santander, 39008, Spain
-
Hospices Civils de Lyon HCL
Lyon, 69002, France
-
ICO L'Hospitalet - Hospital Duran i Reynals
Barcelona, 08908, Spain
-
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, 47014, Italy
-
Klinikum Chemnitz gGmbH
Chemnitz, 09113, Germany
-
Norfolk & Norwich University Hospital
Norwich, NR4 7UY, United Kingdom
-
Ospedale Santa Chiara AO Universitaria Pisana
Pisa, 56126, Italy
-
Ospedali Riuniti Di Ancona
Ancona, 60126, Italy
-
Policlinico Universitario Agostino Gemelli
Rome, 00168, Italy
-
Pratia Onkologia Katowice
Katowice, 40 519, Poland
-
Princess Margaret Cancer Centre University Health Network
Toronto, Ontario, M5G 1X6, Canada
-
Royal Prince Alfred Hospital
Camperdown, 2050, Australia
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital Yonsei University Health System
Seoul, 03722, South Korea
-
Sheba Medical Center
Ramat Gan, 5266202, Israel
-
Sourasky Medical Center
Tel Aviv, 64239, Israel
-
St Francis Hospital & Health Centers Indiana Blood and Marrow Transplantation Franciscan Health
Indianapolis, Indiana, 46237, United States
-
Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
Kielce, 25 734, Poland
-
The Catholic University of Korea Seoul St Mary s Hospital
Seoul, 06591, South Korea
-
The Christie NHS Foundation Trust Christie Hospital
Manchester, M20 4BX, United Kingdom
-
Universitaetsklinikum Hamburg Eppendorf
Hamburg, 20251, Germany
-
Universitaetsklinikum Heidelberg
Heidelberg, 69120, Germany
-
Universitatsklinikum Wurzburg
Würzburg, 97080, Germany
-
Uniwersyteckie Centrum Kliniczne
Gdansk, 80 214, Poland
-
Wojewodzki Szpital Specjalistyczny
Biała Podlaska, 21 500, Poland